To evaluate ceftriaxone for the treatment of shigellosis, 94 adult males with acute dysentery were randomly assigned to receive ceftriaxone (1 g), ampicillin (4 g), or saline placebo intravenously in single doses in a double-blind design. Stool cultures were positive for Shigella dysenteriae in 52 patients, S. flexneni in 38 patients, and other species in 4 patients. Both ceftriaxone and ampicillin caused reductions in the mean duration of fever and the means of daily stool frequency 2 to 4 days after therapy versus placebo (P < 0.05). The ability of ceftriaxone to reduce stool frequency during 6 days after treatment was significant in patients with S. flexneri infections (P < 0.05), whereas S. dysenteriae infections were relatively refractory to improvement by both antibiotics. Neither drug had a significant effect on overall duration of diarrhea, blood in stool, or tenesmus. Ampicillin reduced the mean duration of positive stool cultures after treatment from 2.6 days in the placebo group to 1.1 days (P < 0.05), whereas ceftriaxone did not affect the duration of ShigeUla sp. excretion. These results indicate that single intravenous doses of ceftriaxone and ampicillin caused some clinical improvement in acute shigellosis but only ampicillin exerted a bacteriological effect on Shigella sp. excretion.
Shigella sp. infection is an important cause of morbidity and mortality in Bangladesh and other developing countries. Although shigellosis is usually a self-limited disease and does not always require antibiotic therapy, patients with severe colitis are benefited by appropriate antibiotic therapy. Clinical studies have shown that appropriate antibiotic therapy decreases the duration of diarrhea, fever, abdominal pain, and excretion of Shigella organisms in the stool (7, 8, 15) . A practical approach to treatment of shigellosis is single-dose therapy. Gilman et al. (6) found that 4 g of ampicdillin given as a single dose orally was as effective as conventional regimens given for 5 days in patients more than 4 years old with shigellosis.
The need for testing new antibiotics against shigellosis originates from increasing resistance of Shigella species to multiple antibiotics throughout the world (5, 12) . Ceftriaxone, a broad-spectrum cephalosporin, was found to be highly active against many Enterobacteriaceae including Shigella spp. and Salmonella spp. (1, 4, 40) . Also, the prolonged serum half-life of 8 h (14) and the biliary excretion of ceftriaxone (2) made this drug an attractive candidate for use as a single-dose treatment of shigeilosis. To evaluate the clinical efficacy of this drug, a randomized double-blind trial was performed in Bangladesh, using ampicillin and placebo as control groups.
MATERIALS AND METHODS
Adult male patients who reported to the treatment center of the International Centre for Diarrhoeal Disease Research, Bangladesh, having dysentery for <48 h, >20 fecal leukocytes per high-powered field, and no trophozoites of Entamoeba histolytica in stool were included in the study. Patients with complicating illness such as penumonia or pulmonary tuberculosis, a history of allergy to penicillin, or a history-of recent antibiotic therapy were excluded.
Participating patients were requested to remain in the hospital for 7 days.
After obtaining written consent, the patients were randomly allocated to ceftriaxone, ampicillin, or placebo (0.9% NaCl), using a table of random numbers. The medicine was given as 1 g of ceftriaxone (supplied by F. HoffmannLaRoche and Co., Ltd., Basel, Switzerland) dissolved in 30 ml of normal saline, 4 g of ampicillin (Bayer, Leverkusen, Federal Republic of Germany) dissolved in 30 ml of water, or 30 ml of normal saline. The medications were injected intravenously over 5 min as a single dose. All injections were administered in a double-blind manner by a physician who did not participate in the selection of patients or in managing patients during the study. The patients and nursing staffwere not told which medications were given.
Before therapy was begun one fecal specimen was examined microscopically for ova and parasites, and two fresh stool specimens were obtained for culture. Stool cultures were repeated twice daily for 7 days during hospitalization. All specimens were plated on MacConkey agar and salmonella-shigella agar. Typical lactose-negative colonies were picked up and transferred to Kligler iron agar. Finally, the isolates were differentiated with polyvalent typing sera (Burroughs Wellcome Co.) and selective biochemical tests. In vitro antibiotic disk susceptibilities were performed on all Shigella isolates by the Bauer-Kirby method (3). Ceftriaxone and ampicillin disks (BBL Microbiology Systems, Cockeysville, Md.) containing 30 jig of antibiotic were used, and a clear zone of >16 mm in diameter was used to indicate susceptibility.
Treatment groups were compared with respect to number of stools during 24 h, duration of bloody diarrhea, fever, abdominal pain, tenesmus, and positive stool culture during 7 days of observation. The number of stools passed every 24 h was determined by requesting patients to place a metal disk through a slot into a box every time they passed a stool. Each morning the physician counted the disks and emptied the box to start the next 24-h period. Diarrhea was defined as three or more loose or watery stools per day. For the final 32 patients in the study, accurate stool weights were measured Responses to treatment. The two antibiotic treatments had no discernible effects on the durations of diarrhea, passage of visible blood, abdominal pain, or tenesmus when compared with the placebo controls ( Table 2 ). The mean durations of fever, however, were reduced significantly by both treatments (P < 0.05). The mean duration of positive stool cultures for Shigella spp. was reduced significantly by ampicillin treatment (P < 0.05) but not by ceftriaxone. The mean cumulative number of stools passed during 6 days after treatment was highest in the placebo group, but the reductions produced by treatment with ampicillin and ceftriaxone were not statistically significant (P > 0.05).
Considering the daily frequencies of passing stool after antibiotic treatment, ceftriaxone caused a significant reduction in the mean number of stools per day, evident on day 2 after treatment ( Fig. 1) . The effect of ampicillin on daily stool frequency was significant on day 4 after treatment. For the patients who had daily fecal weights measured, those who received ceftriaxone showed a smaller mean fecal weight on day 1 after the start of treatment, 298 g, than the placebo group did, 570 g (P < 0.05). Patients treated with ampicillin showed a more gradual reduction in the mean of daily stool weights, which on day 7 after the start of treatment was 185 g versus 408 g for patients treated with placebo (P < 0.05).
Effects of ShigeUa species and resistance to ampicillin on responses to treatment. Analysis of clinical responses by species showed that in the placebo group the patients infected with S. dysenteriae had a greater mean number of stools passed during the 6 days of observation than did patients infected with S. flexneri (P < 0.05) ( Table 3 ). For patients infected with S. dysenteriae, treatment with both ampicillin and ceftriaxone resulted in reductions in the mean numbers of stools passed, but the differences between their means and that of the placebo group were not statistically significant (P > 0.05). For patients infected with S. flexneri, ceftriaxone treatment resulted in a significant reduction in the mean number of stools passed (P < 0.05), whereas ampicillin treatment did not cause a significant reduction (P > 0.05). Of the eight patients infected with S. flexneri and treated with ampicillin, three were infected with ampicillinresistant strains. The presence of ampicillin resistance was shown to correlate with an increase in number of stools passed in the ampicillin-treated patients but the difference was not statistically significant (P > 0.05).
The action of antibiotic in clearing Shigella spp. from stool was analyzed by species (Table 3 ). In the placebo group, the mean durations of fecal excretion of the two species of Shigella were similar. For patients infected with S. dysenteriae, ampicillin caused a significant reduction in fecal excretion (P < 0.05), whereas ceftriaxone did not. For patients infected with S. flexneri, treatments with both ampicillin and ceftriaxone caused reductions in the mean (4 g) and ceftriaxone (1 g). Brackets show 1 standard error of the mean (SEM). *Significant reductions in the means of daily stool frequencies compared with the placebo group were noted on day 2 for ceftriaxone and day 4 for ampicillin (P < 0.05).
durations of excretion, but the differences from that of the placebo group were not significant (P > 0.05). The presence of ampicillin resistance was associated with a significantly greater mean duration of Shigella sp. excretion in patients treated with ampicillin (P < 0.05).
Adverse reactions. Two patients vomited immediately after injections of ceftriaxone. Otherwise, there were no adverse reactions to drug therapy.
DISCUSSION
The inclusion of a placebo group in this study allowed us to compare the therapeutic efficacies of antibiotics with no treatment in a disease that is nearly always self-limited. Other treatment studies of shigellosis that have used placebo controls have also shown significant clinical responses to ampicillin given orally (7, 15) . Our results confirm that shigellosis is self-limited and that, in fact, the durations of diarrhea (defined as three or more unformed stools per day), abdominal pain, and tenesmus after treatment were similar in the treated and placebo groups. However, more rapid clinical improvement, as shown by reductions of fever and stool frequencies on certain days, was observed in patients treated with both ceftriaxone and ampicillin when compared with placebo. This clinical response is consistent with results with other beta-lactam antibiotics including ampicillin and pivmecillinam (8) . Furthermore, the observed responses when drugs were given by the intravenous route suggest that the antibiotics exerted their therapeutic activities in tissues rather than in the intestinal lumen.
Other cephalosporin antibiotics, however, have shown poor results against shigellosis. Both cephalexin (9) and cefamandole (11) failed to give satisfactory clinical or bacteriological responses. The failure of cephalexin could be attributed to relatively high MICs of about 5 pLg/ml for the Shigella sp. strains, but cefamandole showed better in vitro activity with MICs of c0.4 ,ug/ml. Ceftriaxone is even more active against tested Shigella organisms, with MICs in the range of c0.006 to 0.2 ,ug/ml (10) , and this greater potency may explain in part its better clinical efficacy compared with other cephalosporins.
The patients with shigellosis in this study were infected most frequently with S. dysenteriae 1 and S. flexneri. S. dysenteriae 1 is known to cause epidemics of clinically severe disease, whereas S. flexneri is the most prevalent endemic species in developing countries. Although our study provided the opportunity to compare these two species, our results must be interpreted in the light of differences between the species. The natural courses of patients with these two species, as shown in the placebo group, were that patients infected with S. dysenteriae passed more than twice as many stools during 6 days as did patients infected with S. flexneri. The effect of ceftriaxone in reducing stool frequency during 6 days was significant only in patients infected with S. otic. A requirement for more antibiotic for S. dysenteriae infection would be consistent with the extensive colitis often caused by this species compared with the usually more limited rectosigmoid infection caused by S. flexneri (13) . Failure of ceftriaxone treatment to clear Shigella organisms rapidly from stools was shown in this study and would seem discordant with the clinical response to this drug. The reason for the bacteriological inactivity was not in vitro resistance of the bacteria because all strains in our patients were shown to be susceptible. Studies of normal volunteers showed that ceftriaxone after an intravenous dose was excreted into the bile but was microbiologically inactive in the feces in four of seven subjects (2, 14) . This suggests that beta-lactamases of colonic bacteria degrade ceftriaxone and may explain why lumenal Shigella organisms are not eradicated by this treatment. Ampicillin, on the other hand, exerted a significant shortening of fecal excretion of Shigella spp. despite its susceptibility to beta-lactamases in the gut lumen. The consequence of the poor bacteriological activity of ceftriaxone against fecal Shigella organisms is that treated patients would remain infectious to their contacts. The period of infectiousness was limited, however, to only a few days and this consideration should not deter its use for achieving a clinical cure. The single-dose form of treatment offers convenience and can be expected to be particularly effective in S. flexneri infections.
The potential usefulness of ceftriaxone for shigellosis will be in geographic areas where resistance to ampicillin and trimethoprim-sulfamethoxazole occurs. In our study only eight isolates of ampicillin-resistant Shigella spp. were obtained, and these eight patients were not allocated to treatment with ceftriaxone. By in vitro testing these isolates were all susceptible to ceftriaxone. Further testing of ceftriaxone in shigellosis due to ampicillin-resistant strains will be required before its clinical usefulness is completely defined.
